DermNaPort

The new Nano-Lipid-Vehicle

To bring Pharmacia, Extracts and

Essential oils in high concentration in

and through the skin.

Monterrey, Mexico 2007

A new and effective topic procedure

for the localised treatment of local illnesses

using proven ingredients

without systemic side effects

Applying Nano-Technology

SKINCONNECTIVE TISSUE

Joints, Tendons

• Acné• Herpes Zoster• Neurodermitis• Healing/regeneration• Couperosis• Spider Naevi• Hemangioma• Skin pigmentation• Stretch marks• Cellulitis• Wrinkles• Tromboflebitis• Mycosis• Alopecy• Bags under the eye• Post-Zoster neuralgy

• Rheumatic Arthrtis

• Osteoarthritis

• Chronic Poliarthritis

• Gout

• Tendopathy

• (CRPS)

• Knee

• Hand

• Hips

• Foot

APPLICATION OPORTUNITIES FOR OUR DERMNAPORT SYSTEM

DermNaPortSystem

Nº of micelles (n) = 1,9 x 1018

d 10 Nanometer

Phase surface

= n d² = 1,9 1018 3,14 10-16 = 600 m²

Nano emulsions have specialy large phase surfaces

HOW DOES OUR NANOTECHNOLOGY WORK?

1 cm

HOW DOES OUR NANO-LIPID-VEHICLE WORK?

Due to spetialy large phase surface nano emulsions can absorb largequantities of active ingredients.Nano emulsions, together with active ingredients, can deeply penetrate the skin.

skin

Without Nano-technology With Nano-technology

skin

Due to the characteristics of this nano technology, our state of the art vehicleallows for a very effective transdermal transport of virtually any product onthe market

Effectiveness of actual commercial products is very limited(lotions, gels, crémes, sprays, etc.)

COMPARISON

Nano-Gel(Home

application)

Liquid(for clinical use)

DermNaPort

3 CUTANEOUS PENETRATION ALTERNATIVES

Inter-cellular

Trans-cellular

Trans-glandular

transfolicular

Besides the inter-cellular method, other penetration options do exist:

The transfolicular option is for veterinary medicine of great importance.

These Nano-preparations allow for effective topic therapy with highly effective active ingredients for local illnesses.

Such active ingredients have a very high toxicity index when taken systemicaly:

DERMNAPORT PRINCIPLE

traditional DermNaPort

System

Oral intake

Systemic:• Reduced concentration on local problem• limited effectiveness• Damages to the body

Tópic:• High concentration on local problem• Maximum effectiveness• No damages to the body

Toxicity index Local application

TYPES OF ADMINISTRATION

DermNaPortSYSTEM

Clinical administration: Home administration

General Presentation: Nano-Gel

- Lower concentrations- Easy & safe administration- For post-treatment use- Without side effects

Presentation: Liquid

- Constant medical supervision - High concentrations- More effective- Individual dosage- Precise dosage- Máximum skin penetration- Without side effects

PROBLEM:

PAIN

• In the previously mentioned cases, pain is an

essential factor

• Overall, pain is a problem that cuts deep into

society and its functional and intrapersonal

relationships.

SITUATION IN MEXICO

• 10% of the population suffers from reumatic illness.

• 50% of the working population do suffer at least one back pain episode per year.

• 80% of the population suffer of an acute back pain during their livespan.

• 3 millions suffer from osteroarthritis.

• 10 millions have degenerative arthritis.

• 30 millions take pain medication.

RESULTS

WHO CAN BENEFIT FROM OUR SYSTEM?

CRPSJoint degeneration

TendinopatiaLumbalgia

GoutPolineurpathy

RheumatismArthritis & Poliartritis

Patients who suffer:

SUCCESS RATES (PER BODY AREA)

Overall success rate: 80% Total number of treatments: 147 Average number of treatments: 7

Neck: 80%Nº. T.: 11Nº.D.: 75

Shoulder/ Hands 85%Nº.T.: 77Nº.D.:359

Ellbow/ Hands: 100 %Nº.T.: 31Nº.D.: 96

Thigh: 75 %Nº.T.: 3Nº.D.: 8

Knee: 100 %Nº.T.: 20Nº.D.: 59

Tests were made on 20 cases in German pain managment centers which have undergoneprevious unsuccessfull treatments

SUCCESS RATES PER SKIN AND JOINT CONDITION

General succes rate: 74% (on previously unsuccessful treated patients)

CONCLUSIONS

High efficiency rate (aprox. 80%)

Altos niveles de efectividad

Only administered localy

Use of injections not neccesary

No secondary toxic effects

Does not react when mixed with other medication

Can be safely administered on polimorbide patients

Easy administration

It is a universal vehicle for topic administration

Does not irritate the skin

BIBLIOGRAFÍA

Prof. Dr. Med. LotzTenure track Professor at the University of Ulm in the medicine field. Medical specialist in anesthesia and pain management. Director of pain management center in Bad Liebesspringe (DE)

Dr. Med. SteinbergPATerapeuta para el dolor. Private medicine sector. Medical specialist in pain management.

Today in Mexico we do have done more then 100 succesfull new cases.

THANK YOU VERY MUCH

FOR YOUR ATTENTION

Wherever possible our innovations and

developments are beeing protecded by

national and international patents and

patents applications